[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620317":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":29,"responsibleParty":79,"collaborators":81,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":89,"sex":95,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":10,"studyType":101,"phases":10,"briefSummary":102,"conditions":103,"keywords":107,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"Children's Hospital Medical Center, Cincinnati","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Second Measles Vaccine (MV2)",null,"Participants who receive second measles vaccine.",{"label":13,"type":10,"description":14,"interventionNames":10},"First Measles Vaccine (MV1)","Participants who obtain the first measles vaccine.",[16],{"name":17,"affiliation":5,"role":18},"Alexandra Power-Hays, MD","PRINCIPAL_INVESTIGATOR",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Teresa Latham","CONTACT","513-803-7922","Teresa.Latham@cchmc.org",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Amy Shova","(513) 803-1917","Amy.Shova@cchmc.org",[30,51,65],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Cincinnati Children's Hospital Medical Center","RECRUITING","Cincinnati","Ohio","45229","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-84.51439,39.12711,{"lat":42,"lon":41},[45,49],{"name":46,"role":22,"phone":47,"phoneExt":10,"email":48},"MacKenzie Tasset","513-803-4856","MacKenzie.Tasset@cchmc.org",{"name":50,"role":18,"phone":10,"phoneExt":10,"email":10},"Charles Quinn, MD",{"facility":52,"status":32,"city":53,"state":54,"zip":10,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Korle Bu Teaching Hospital","Accra","Ghana","GH",{"type":39,"coordinates":57},[58,59],-0.1969,5.55602,{"lat":59,"lon":58},[62,63],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"name":64,"role":18,"phone":10,"phoneExt":10,"email":10},"Catherine Segbefia, MBChB, FWACP, GGCPS",{"facility":66,"status":32,"city":67,"state":10,"zip":10,"country":68,"countryCode":10,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Bugando Medical Centre","Mwanza","Tanzania",{"type":39,"coordinates":70},[71,72],32.9,-2.51667,{"lat":72,"lon":71},[75,77],{"name":76,"role":22,"phone":23,"phoneExt":10,"email":24},"Teresa Latham, PhD",{"name":78,"role":18,"phone":10,"phoneExt":10,"email":10},"Emmanuela Ambrose, MD, MMED",{"type":80,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[82,84],{"name":83,"class":6},"Thrasher Research Fund",{"name":85,"class":86},"National Institutes of Health (NIH)","NIH","100620317","verifying-antibodies-after-live-immunization-delivery-valid-a-study-of-measles-vaccine-immunogenicity-in-children-with-sickle-cell-disease-100620317",false,"NCT07356050","Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease","Verifying Antibodies After Live Immunization Delivery (VALID): a Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease","VALID","Inclusion Criteria:\n\n1. Participants with confirmed Sickle Cell Disease.\n2. Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines.\n3. Willing and able to provide informed consent\n4. Ability to comply with study related evaluations and follow-up visits.\n\nExclusion Criteria:\n\n1\\. Known primary immunodeficiency syndrome, cancer, or acquired immunodeficiency syndrome (AIDS) that would preclude vaccination with live virus vaccines.","ALL","6 Months","6 Years",{"count":99,"type":100},130,"ESTIMATED","OBSERVATIONAL","The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)",[104,105,106],"Sickle Cell Disease","Measles Vaccination","Sickle Cell Anemia",[108],"Measles Vaccine Immunogenicity","2026-01-20",{"date":111,"type":112},"2026-01-21","ACTUAL",{"date":114,"type":112},"2025-03-13",{"date":116,"type":100},"2028-12-31",{"name":5,"class":6},3]